BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elsanhoury A, Sanzenbacher R, Reinke P, Abou-El-Enein M. Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev 2017;7:15-9. [PMID: 28971109 DOI: 10.1016/j.omtm.2017.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7:676-685. [PMID: 30063299 DOI: 10.1002/sctm.17-0282] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 22.0] [Reference Citation Analysis]
2 Ogbogu U, Du J, Koukio Y. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions. BMC Med Ethics 2018;19:32. [PMID: 29716594 DOI: 10.1186/s12910-018-0273-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
3 Lam C, Meinert E, Alturkistani A, Carter AR, Karp J, Yang A, Brindley D, Cui Z. Decision Support Tools for Regenerative Medicine: Systematic Review. J Med Internet Res 2018;20:e12448. [PMID: 30567696 DOI: 10.2196/12448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Mirones I, Moreno L, Patiño-García A, Lizeaga G, Moraleda JM, Toribio ML, Pérez-Martínez A; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas., Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Española de Hematología y Oncología Pediátricas. [Immunotherapy with CAR-T cells in paediatric haematology-oncology]. An Pediatr (Engl Ed) 2020;93:59.e1-59.e10. [PMID: 32107177 DOI: 10.1016/j.anpedi.2019.12.014] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Goula A, Gkioka V, Michalopoulos E, Katsimpoulas M, Noutsias M, Sarri EF, Stavropoulos C, Kostakis A. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. J Clin Med Res 2020;12:780-6. [PMID: 33447311 DOI: 10.14740/jocmr3964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, Gee AP, Dominici M, Silva DN, Baharvand H, Hajizadeh-Saffar E. Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. Front Cell Dev Biol 2020;8:547653. [PMID: 33392179 DOI: 10.3389/fcell.2020.547653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Hills A, Awigena-Cook J, Genenz K, Ostertag M, Butler S, Eggimann AV, Hubert A. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact. Cytotherapy 2020;22:772-779.e1. [PMID: 33046395 DOI: 10.1016/j.jcyt.2020.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol 2020;21:e104-16. [PMID: 32007196 DOI: 10.1016/S1470-2045(19)30729-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 28.0] [Reference Citation Analysis]